{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9"},{"groupId":"OG001","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"300"}],"units":"Participants"}],"title":"Evaluable AL and HSCT Patients at Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"16.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"Evaluable AL and HSCT Patients at 2 Months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1"},{"groupId":"OG001","value":"14.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Evaluable AL and HSCT Patients at 12 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"303"},{"groupId":"OG001","value":"300"}],"units":"Participants"}],"description":"Musculoskeletal conditions included at least one occurrence of arthralgia, arthritis, gait abnormality or tendinopathy.","groups":[{"description":"Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.\n\nlevofloxacin: Given PO or IV","id":"OG000","title":"Arm I (Levofloxacin)"},{"description":"Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.","id":"OG001","title":"Arm II (Standard of Care)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients who submitted musculoskeletal Case Record Form (CRF) combined from both Acute Leukemia (AL) and Hematopoietic stem cell transplantation (HSCT) cohorts at enrollment. Ineligible and withdrew of Consent prior to treatment were excluded.","reportingStatus":"POSTED","timeFrame":"Enrollment, 2 months and 12 months post infection observation period","title":"Comparison of the Percentage of Patients Having Incidence of Musculoskeletal Adverse Events Including Tendinopathy (Tendonitis and Tendon Rupture) Between Arms","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}